TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing laparoscopic cholecystectomy or Lap-Band ASA III or less~Exclusion Criteria:~* Patients who refuse consent~* Are converted from laparoscopy to open surgery~* Are allergic to bupivacaine~* Are unable to followup

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- On-Q pain pump (Type: EXPERIMENTAL): Bupivacaine
- Placebo/control (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects undergoing outpatient surgeries (laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy) under general anesthesia requiring rocuronium-induced neuromuscular blockade~2. Male or female patient 18 years and older~3. Able to consent~4. American Society of Anesthesiologist (ASA) physical status of I, II, or III~Exclusion Criteria:~1. Participating in another interventional study drug within 30 days prior to their recruitment~2. Special population (Pregnant, Inmate, Breastfeeding)~3. History of allergy to sugammadex or rocuronium~4. Any medication known to interfere with NMBA or sugammadex~5. Presence of any clinical condition as determined by the investigator that exclude the patient from the trial such as COPD, CKD, and neuromuscular or neurodegenerative diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sugammadex (Type: ACTIVE_COMPARATOR): * If spontaneous recovery has reached second twitch after TOF: 2 mg/kg~* If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg~* When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg
- Neostigmine (Type: ACTIVE_COMPARATOR): 50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Immunogenicity of a HPV Vaccine in SLE

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~SLE patients~1. Female patients aged 18-35 years~2. Fulfilling the American College of Rheumatology (ACR) criteria for the classification of SLE~3. Having participated in the investigators' original HPV study in 2010~4. Able to give written informed consent~Controls~1. Women aged 18-35 years, matched those of SLE patients recruited~2. No known chronic medical diseases~3. Having participated in our HPV study in 2010

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- SLE patients (Type: None): SLE patients who received HPV vaccination
- Control subjects (Type: None): Healthy subjects who received HPV vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of narcolepsy~* Good general health~* Willing and able to comply with the study design and schedule and other requirements~Exclusion Criteria:~* If female, pregnant or lactating~* Customary bedtime later than midnight~* History of significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history~* Any other clinically relevant medical, behavioral or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness~* History of significant cardiovascular disease~* Body mass index \>34~* Excessive caffeine use - \> 600 mg/day of caffeine or \> 6 cups of coffee/day~* History of alcohol or drug abuse within the past two years~* Nicotine dependence that has an affect on sleep

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo, Then ADX-N05 (Type: EXPERIMENTAL): Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).
- ADX-N05, Then Placebo (Type: PLACEBO_COMPARATOR): Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Autologous Platelet-rich Plasma With Hyaluronic Acid for the Treatment of Osteoarthritis of the Knee Joint

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with osteoarthritis of knee (by American College of Rheumatology Criteria) and Kellgren-Lawrence grade I \~ III~* More than 40 out of 100-mm VAS scale for pain at screening and baseline~* Participant is willing and able to give informed consent for participation in the study~Exclusion Criteria:~* Patients with Hb values \< 10 g/dl and platelet values \< 100,000/ul~* Patients with a current or medical history of autoimmune disease~* Recent fever ( within 2 weeks) or serious illness~* Local infection at the site of the procedure~* Corticosteroid injection at treatment site within 1 month~* Systematic use of corticosteroids within 2 weeks~* Female participants who are pregnant, lactating or planning pregnancy during the course of the study~* Patients who have been administered with immunosuppressants within the past 6 weeks~* Patients who are enrolled in any other clinical trials within 4 weeks~* Patients who the principal investigator considers inappropriate for participation in the clinical trial for reasons other than those listed above

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PRP group (Type: EXPERIMENTAL): Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
- Hyaloronan group (Type: ACTIVE_COMPARATOR): Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients shall have normal organic function such as liver function, Cardiac function and renal function;~2. male or female age \>18 years old;~3. diagnosis GI cancer with histology;~4. Chronic neurotoxicity grade is 2 or more~5. Karnofsky Performance scores should be 80 or more~6. patients are in oxaliplatin-based chemotherapy courses or no more than 21 days after last oxaliplatin usage for patients who will discontinue oxaliplatin usage.~7. without uncured tumor except GI cancer,~8. Patients should be expected to live no shorter than 3 months~Exclusion Criteria:~1. patients who is receiving anti-neurotoxicity treatment;~2. WBC\<4.0×109/L，ANC\<1.5×109/L,PLT\<100×109/L，Hb\<90g/L,TBIL\>1.5Limitation;BUN）\>1.5Limitation；Cr）\>1.5Limitation；ALT or AST\>2.5Limitation（without liver metastasis）；ALT or AST）\>5Limitation（with liver metastasis）;~3. heart dysfunction;~4. brain metastasis with symptoms;~5. peripheral nervous system or central nervous system abnormal including diabetes mellitus patients with neuropathy;~6. in situation of oxaliplatin-based chemotherapy progressed, the next chemotherapy regime should not contain agents which will cause neurotoxicity (such as paclitaxel and cisplatin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo+oxaliplatin-based chemotherapy (Type: PLACEBO_COMPARATOR): equal saline as placebo, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
- GM+oxaliplatin-based chemotherapy (Type: EXPERIMENTAL): monosialotetrahexosylganglioside Sodium Injection, 40mg or 60mg, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* hyperlipidemia~* urinary protein~* diabetes~Exclusion Criteria:~* previous rosuvastatin treatment \< 6 months prior to Visit 1~* statin intolerance~* severe hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Rosuvastatin 10 mg
- 2 (Type: EXPERIMENTAL): Rosuvastatin 40 mg
- 3 (Type: ACTIVE_COMPARATOR): Atorvastatin 80 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Personally signed and dated informed consent document.~* Randomized and treated with subcutaneous investigational product in a tanezumab study and has completed the study or been withdrawn from the study.~* Actual or planned total knee, hip or shoulder replacement surgery during the tanezumab study.~* Willing and able to comply with scheduled visits and other study procedures.~Exclusion Criteria:~- None.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: OTHER): long-term observational study of subjects from tanezumab parent study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~IFG, or IGT BMI 27.0-37.0 kg/m2~Exclusion Criteria:~DM, CAD, severe anemia, kidney or liver disease, hx of pancreatitis, gallstones, ETOH abuse, personnel or family history of medullary thyroid carcinoma or MEN-2

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
- liraglutide (Type: ACTIVE_COMPARATOR): Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Patient with PBC defined by 2 in 3 of the following criteria Positive antimitochondrial antibody type M2. Abnormal serum alkaline phosphatases (ALP \> 1,5N) and aminotransferase (AST or ALT \> 1N) activities.~Histological hepatic injuries consistent with PBC from biopsy specimens of at least 10 mm.~* Patient treated with UDCA at the dose of 13 to 15 mg/kg/d (consistent to the AMM)~* Patients showing an incomplete biochemical response to UDCA as defined by : ALP \> 1,5N or AST \> 1,5N or total bilirubin \>17 µmol/l (with conjugated bilirubin \> 8 µmol/l) after ≥ 3 months of UDCA at the dose of 13 - 15 mg/kg/day.~Exclusion Criteria:~* Unsigned consent.~* Patient with no social insurance or having medical assistant of state~* Ascites or gastrointestinal bleeding (or history of these)~* Serum total bilirubinemia \> 50 μmols/L (3 mg/dl) (sample \< 3 months)~* Serum albuminemia \< 35 g/l (sample \< 3 months)~* Prothrombin index \< 70% (sample \< 3 months)~* Platelet count \< 100000/mm3 (sample \< 3 months)~* Treatment with corticosteroids, immunosuppressive agents, fibrates (or other PPAR-agonists) or statin in the last 3 months~* Any comorbidity susceptible to cause a hepatic impairment (HBV, HCV, or HIV seropositivity; excessive alcohol consumption; hemochromatosis, Wilson's disease, α1 antitrypsin deficiency; celiac disease; uncontrolled dysthyroidism; autoimmune hepatitis, inflammatory colitis)~* Any severe comorbidity decreasing life expectancy~* Intolerance or hypersensitivity to fibrates, to one of these components or other fibrates in general~* Known photosensitivity reaction to fibrates~* Pregnancy or desire of pregnancy~* Breast-feeding~* Renal failure (clearance of creatinine \< 60 ml/mn)~* Patient with congenital galactosemia, syndrome of glucose malabsorption, lactase deficiency due to the presence of lactose in tablets of bezafibrate 400 mg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bezafibrate (Type: EXPERIMENTAL): 400 mg/Day
- Placebo (Type: PLACEBO_COMPARATOR): 1 tablet/ day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In a single-center study, 63 patients (32 males and 31 females) diagnosed with nonalcoholic fatty liver disease were recruited from the outpatient clinic and evaluated for the study.~Exclusion Criteria:~* Patients with history of unstable angina, MI, CVA or major surgery within the six months preceding entrance to the study.~* Patients with unbalanced endocrine disease or any disease that might affect absorption of medications.~* Patients with plasma creatinine \> 1.5 mg/dl, and electrolyte abnormalities.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metformin, Adiponectine, Arterial Compliance (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male, 2-\<18 years Hemophilia A, based on documented prior testing and/or screening laboratory Patients who had received regular prophylaxis/bleeding prevention treatment, totally/partially with rFⅧ. Regular prophylaxis/bleeding prevention treatment is defined as that proportion of weeks (≥2 infusion/week) of total treatment weeks≥80%\[10\] , and total duration ≥12 weeks. During the regular prophylaxis period, if there were consecutive 4 weeks that \<2 infusion/week, the beginning day of the 4 weeks is defined as the end of regular prophylaxis.~Available patient medical data record Written informed consent by parent/legal representative. Consent should be sought from subjects if appropriate~Exclusion Criteria:~* Patients with measurable inhibitor activity at baseline and history of FVIII inhibitor antibody formation (≥0.6BU by Bethesda assay at two different time points, documentation must be available) Any individuals with another bleeding disease that is different from hemophilia A (e.g, von Willebrand disease, hemophilia B)

- Gender: MALE
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Chinese hemophilia A pediatric patients with medical records who had accepted regular prophylaxis, totally/partially with rFⅧ between Nov. 1st 2007 and May 31st 2013

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Arachidonic Acid Treatment Against Schistosomiasis Infection in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* consent from parent or legal guardian~* clinically confirmed schistosomiasis~Exclusion Criteria:~* not infected with schistosomiasis~* less than 6 or greater than 15 years of age

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Praziquantel (PZQ) (Type: ACTIVE_COMPARATOR): A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.
- Arachidonic acid (ARA) (Type: EXPERIMENTAL): A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.
- PZQ + ARA (Type: EXPERIMENTAL): A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete